Advertisements

Cyclopam Suspension

Quick links to important sections

Cyclopam Suspension

Advertisements
Advertisements

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Cyclopam Suspension

Property Description
Active Ingredients Dicyclomine, Dimethicone, Simethicone
Form Oral Suspension (liquid preparation)
Pharmacological Class Antispasmodic and Antiflatulent
Primary Mechanism Muscle relaxation and defoaming action
Origin Synthetic and Polymer-based

The Identity and Classification of Cyclopam Suspension

Cyclopam Suspension is a liquid, oral, fixed-dose combination (FDC) medicine classified primarily as an antispasmodic and antiflatulent. It is designed to be swallowed and works within the gastrointestinal tract.

This medicine is categorized as an FDC preparation because it integrates two functionally distinct groups of active pharmaceutical ingredients into a single preparation. The classification of Dicyclomine as an anticholinergic agent, primarily used for its muscle-calming effects, is a pharmacological principle. The term suspension indicates that the active ingredients are finely dispersed but not entirely dissolved within an aqueous vehicle, which makes the preparation suitable for pediatric patients or individuals who benefit from an easier-to-swallow liquid preparation.


Composition: Dicyclomine and Antiflatulent Components

The active ingredients in the medicine are Dicyclomine, Dimethicone, and Simethicone, working synergistically to address common sources of abdominal pain. The formulation is synthetic in origin; Dicyclomine is a manufactured chemical compound, while Dimethicone and Simethicone are organosilicon polymers that function as surface-active agents.

Dicyclomine is the muscle-calming component, which helps regulate the signals that trigger involuntary contractions of the gut's smooth muscles. This specific combination integrates the muscle-calming effect of Dicyclomine with the antiflatulent properties of Dimethicone and Simethicone. This combined approach is designed to simultaneously target spasms and eliminate pressure caused by trapped gas.


General Purpose and Benefit

The general purpose of Cyclopam Suspension is to provide targeted relief from abdominal discomfort caused by two factors: intestinal spasms and excess gas accumulation. It is an oral preparation intended to quickly address the symptoms associated with these issues, such as the acute, episodic discomfort common in infant colic or functional dyspepsia.

The formulation is structurally engineered to offer a comprehensive benefit by simultaneously calming the excessive muscle activity that results in cramping pain and assisting the body in eliminating pressure caused by painful bloating, thereby providing multi-faceted symptomatic relief within the digestive system.

Regulatory References

  1. Dicyclomine: MedlinePlus Drug Information
Advertisements

What side effects are possible with Cyclopam Suspension?

Possible Side Effects and Safety Information

The safety profile of Cyclopam Suspension is primarily defined by the systemic effects of its active anticholinergic component, Dicyclomine, as documented in government regulatory sources. Adverse reactions are grouped by the affected body system (System-Organ Class) and may affect the central nervous system, eyes, and urinary function due to the drug’s mechanism of action.

Commonly Documented Adverse Reactions

Side effects frequently reported in regulatory prescribing information for Dicyclomine include dry mouth, dizziness, blurred vision, nausea, drowsiness, and nervousness. These effects are often noted as being dose-related and typically associated with the systemic absorption of the antispasmodic agent.

Serious Adverse Reactions and Constraints

Official labels detail serious events such as apnea (cessation of breathing) and seizures in infants, and symptoms of anticholinergic toxicity (e.g., confusion, delirium) in sensitive individuals. The medicine is contraindicated in infants under six months of age and in nursing mothers due to these documented risks. Furthermore, its use is restricted in patients with conditions like glaucoma, obstructive diseases of the urinary or gastrointestinal tracts, and myasthenia gravis, as the drug’s effects may worsen these conditions.

Population-Specific and Time-Related Safety Notes

Caution is advised in the older adult population due to increased sensitivity to anticholinergic-related CNS side effects. Regulatory notes also indicate that adverse effects, particularly those affecting the central nervous system, are most likely to appear at the initiation of treatment and may impair a person's ability to perform activities requiring mental alertness. The label also notes a risk of heat prostration due to decreased sweating when used in high temperatures.

Advertisements

Overdose and Emergency Response

Overdose involving Cyclopam Suspension is primarily associated with the anticholinergic toxicity profile of its systemic component, Dicyclomine. Symptoms documented in regulatory labeling involve severe Central Nervous System (CNS) and systemic effects.

System Documented Manifestations Severe Outcomes
CNS/Neuromuscular Excitement, confusion, agitation, hallucinations, short-term amnesia, muscular weakness. Seizures, coma, paralysis.
Cardiovascular/Ocular Rapid heartbeat (tachycardia), dilated pupils, blurred vision. Cardiovascular collapse.
Systemic Hot, dry skin, fever (heat prostration). Respiratory collapse, death (reported in infants).

Regulators document that an overdose may quickly escalate to life-threatening complications, requiring urgent intervention. Individuals must seek immediate medical attention or contact emergency services immediately upon suspected overdose or the onset of severe symptoms. Management documented in official sources involves symptomatic and supportive treatment, including procedures such as gastric lavage and the administration of activated charcoal.

A specific concern documented in official prescribing information relates to infants, who are highly susceptible to severe and unique overdose manifestations, including serious respiratory symptoms and a documented risk of death. Older adults may also experience enhanced susceptibility to CNS effects, such as confusion.

Advertisements

Therapeutic Uses of Cyclopam Suspension

What Cyclopam Suspension treats: main uses and benefits

The purpose of Cyclopam Suspension, an antispasmodic and antiflatulent liquid preparation, is to offer supportive symptomatic assistance across specific domains of functional gastrointestinal discomfort. It is commonly used when symptoms create noticeable interference with daily functioning, often during acute or recurrent episodes.

The primary active components are commonly used in contexts associated with managing symptoms of functional bowel or irritable bowel syndrome, conditions characterized by painful cramping and altered bowel movements.

Therapeutic Focus

The medicine is relevant in conditions characterized by episodic or fluctuating manifestations, applied during phases when symptoms intensify and supportive symptom management is needed. It helps address symptom clusters that may appear suddenly, including spasmodic abdominal pain, intense cramps, painful bloating, intestinal distension, and flatulence.

It provides support that helps ease the overall symptom burden, particularly in conditions such as Irritable Bowel Syndrome (IBS) and Infantile Colic where symptoms relate to both muscle activity and gas. The primary benefit is to assist with easing the combined distress, contributing to improved comfort during symptomatic periods.


Quick Fact: Symptomatic Relief Domains The suspension is relevant in its application to symptoms that involve both the muscle activity and the gas component of digestive distress, helping to ease the overall symptom load.

Advertisements

Eligibility and Restrictions for Use

The eligibility for Cyclopam Suspension is strictly defined by the official regulatory documentation of its active component, Dicyclomine, establishing clear groups who can and cannot use the medicine.


Populations for Whom Use is Contraindicated

Use is prohibited for the following patient groups and conditions, as they constitute absolute contraindications:

  • Infants less than 6 months of age.
  • Nursing mothers (women who are breastfeeding).
  • Patients with obstructive uropathy or obstructive disease of the gastrointestinal tract.
  • Patients with severe ulcerative colitis, reflux esophagitis, glaucoma, myasthenia gravis, or unstable cardiovascular status in acute hemorrhage.

Eligibility and Conditional Restrictions

  • Age Eligibility: Use is established for infants and children 6 months of age and older. Older adults (geriatric patients) should use the medicine with caution due to greater susceptibility to effects.
  • Organ and Comorbidity Restrictions: Use is restricted and requires caution in patients with known hepatic (liver) or renal (kidney) impairment. Caution is also necessary for patients with known or suspected prostatic hypertrophy and certain cardiovascular conditions (e.g., cardiac tachyarrhythmia, coronary heart disease).
  • Pregnancy Status: Use during pregnancy is restricted to cases where it is clearly required.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Cyclopam Suspension focuses on interactions governed by its active ingredients, Dicyclomine and the antiflatulent components. The interaction profile is defined by additive pharmacodynamic effects and altered drug exposure.

Documented Interaction Patterns

Co-administration with other Anticholinergic Agents (including tricyclic antidepressants and certain antihistamines) may result in additive anticholinergic effects, such as enhanced dry mouth or urinary retention, as documented in official labeling. Combining the suspension with CNS Depressants (including alcohol and narcotic analgesics) may lead to additive CNS depression, increasing the risk of sedation.

Exposure and Timing Constraints

Interaction constraints relate to absorption and motility. The effects of Antiglaucoma Agents may be antagonized by Dicyclomine, constituting a formal restriction in patients with glaucoma. Simultaneous use of Antacids should be avoided as they interfere with Dicyclomine’s absorption. Dicyclomine, by reducing gastrointestinal motility, may increase the serum concentration of certain co-administered drugs, such as slowly dissolving dosage forms of Digoxin. Regulatory documents also note that the Geriatric population may be more susceptible to adverse events resulting from pharmacodynamic interactions, particularly the combined anticholinergic burden.

Advertisements

Mechanism of Action

Modulation of Cholinergic Signaling Pathways

This domain involves the action of dicyclomine, which acts as an anticholinergic agent. It blocks the action of the neurotransmitter acetylcholine at its receptor sites on smooth muscle cells, initiating a cascade that modifies the transmission of nerve-mediated cholinergic signals to target smooth muscle cells.

Direct Smooth Muscle Relaxation

Dicyclomine also exerts a direct antispasmodic effect on the smooth muscles of the gastrointestinal tract. This action is independent of its effect on the nervous system, engaging mechanisms that directly influence the muscle's inherent contractility and contributing to the modification of smooth muscle contractility resulting from direct interaction at the cellular level.

Regulation of Gas Dynamics (Antifoaming Effect)

The second active component, simethicone, engages a mechanism that modifies the physical properties of gastrointestinal contents. It functions as an anti-foaming agent by reducing the surface tension of gas bubbles trapped in the gut, causing them to coalesce into larger bubbles. This reduces the physical presence of small gas bubbles, promoting their coalescence into fewer, larger bubbles.

Advertisements

Dosage and Administration Information

Official Administration Guidelines for Cyclopam Suspension

This section outlines the standardized usage patterns and dosing requirements for Dicyclomine/Simethicone preparations.


Administration Scope

Instruction Detail
Route of Administration The primary route for the suspension is Oral. An injectable form of the Dicyclomine component is also available for Intramuscular (IM) use when oral administration is not feasible.
Dosing Schedule & Frequency The Dicyclomine component has an adult starting dose of 20 mg, which may be increased to a maximum of 40 mg, administered 4 times a day (q.i.d.). The Simethicone component is also commonly dosed 4 times daily.
Timing & Preparation The Simethicone component is typically taken after meals and at bedtime. The liquid preparation must be shaken well before use to ensure proper dispersion of the active ingredients.

Procedural Constraints and Duration

Constraint Detail
Course Duration The Dicyclomine component requires a 2-week trial period; if effectiveness is not observed, treatment should be discontinued. Safety data for doses above 80 mg daily for longer than two weeks are not established.
Age-Group Rules The use of Dicyclomine is contraindicated in infants less than 6 months of age. The safety and efficacy for the primary adult indication have not been established in patients younger than 18 years.
Special Handling If a dose is missed, patients should continue the normal dosing schedule and should not take a double dose. The IM injection of Dicyclomine is restricted to the IM route only and must not be administered intravenously.

Established guidelines define a specific Oral route and a fixed-interval, four-times-daily regimen for this medicine, with defined maximum adult doses. These rules establish a clear, time-limited procedural framework for its use, mandating discontinuation if the 14-day trial period yields no benefit, and strictly excluding its use in infants under 6 months.

Advertisements

Recent Clinical Evidence

Cyclopam Suspension: Recent Clinical Evidence

Evidence for Use in Irritable Bowel Syndrome (IBS)

Research exploring the antispasmodic component (Dicyclomine) was evaluated in studies focusing on conditions characterized by fluctuating or episodic manifestations, such as Irritable Bowel Syndrome. The evidence base primarily relies on systematic reviews and meta-analyses of Randomized Controlled Trials (RCTs) in adults, monitoring outcomes like changes in abdominal pain and overall symptom scores. Findings were mixed across synthesized trials, and long-term effects are not fully established. Research describes that many core trials were conducted in earlier periods, where sample sizes were modest and methodological quality was observed to be not always clearly reported.


Evidence for Use in Infantile Colic

Research examined both the antispasmodic and antiflatulent components (Dicyclomine and Simethicone/Dimethicone) in studies of acute episodes, such as infantile colic, monitoring outcomes like total duration of crying in infants. Research examined the antiflatulent component, and findings were mixed; some studies reported measurements that did not consistently differ from control groups (placebo). Findings indicate that research explored the antispasmodic component, but its use in this population was observed in some studies to be associated with specific patient observations. The certainty remains low for this area, as comparative evidence for the specific fixed-dose combination (FDC) is lacking.


Understanding the Study Landscape and Evidence Quality

The research base for the components of Cyclopam Suspension spans several decades, leading to a situation where evidence consistency varies across studies. For functional gastrointestinal disorders, the evidence level is low to moderate, which indicates the overall certainty derived from the findings is not high. Research describes that many core trials relied on modest sample sizes and varied methodological quality, which means studies provide context but not individual predictions about responsiveness.


Areas of Research Uncertainty and Study Gaps

Research contributes to describing short-term or episodic symptom patterns, but follow-up durations were limited, and long-term effects are not fully established. Data for certain groups remain insufficient, as studies primarily examined adult populations for IBS and infants for colic, with limited information on older adults or those with complex comorbid conditions. Research highlights that evidence contributes to describing symptom patterns, but certainty remains low in several key areas.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Cyclopam Suspension (FAQ)


Q: What is the main difference between Dicyclomine and Simethicone in this medicine?

A: Cyclopam Suspension contains two active components that function differently. Dicyclomine is the antispasmodic component, described as helping to calm excessive muscle contractions (spasms) in the gut. Simethicone is the antiflatulent component, which is included to help reduce pressure from excess gas and bloating.

Q: Is Cyclopam Suspension different from Cyclopam tablets?

A: Regulatory records for the active component Dicyclomine indicate it is available in multiple dosage forms, including a liquid solution (suspension) and solid forms like tablets and capsules. The suspension is a liquid preparation that combines the antispasmodic component with the antiflatulent component in a formula designed to be swallowed.

Q: Can Cyclopam Suspension be used for general stomach pain?

A: Official use descriptions indicate that this medicine is intended to address abdominal discomfort stemming from intestinal spasms and excess gas accumulation within the digestive tract. Regulatory information indicates the medicine is intended after other pain types have been considered.

Q: Does Cyclopam Suspension help with gas or bloating?

A: Official product information suggests that the medicine helps with gas and bloating. The Simethicone component is specifically included as an antiflatulent, or anti-foaming agent. Its purpose is to help relieve discomfort associated with excess gas and bloating by causing small gas bubbles in the gut to combine into larger ones.

Q: What is the purpose of Simethicone in Cyclopam Suspension?

A: The purpose of Simethicone is to act as an antiflatulent and anti-foaming agent. This component is designed to help relieve the pressure and discomfort associated with excess gas and bloating by modifying the physical properties of gas in the digestive system.

Q: Is Cyclopam Suspension available without a prescription?

A: The Dicyclomine component in this fixed-dose combination is typically classified as a prescription-only medicine. Therefore, the entire combination preparation is generally not available without a prescription.

Q: What is the difference between an antispasmodic and an analgesic?

A: This is a classification difference based on mechanism. An antispasmodic (like Dicyclomine) works to relax smooth muscles to relieve cramps at their source. An analgesic (or painkiller) works differently by reducing the body’s perception of pain signals.

Q: How quickly is Cyclopam Suspension expected to start working?

A: Pharmacokinetic studies documented in regulatory reviews indicate that the active component, Dicyclomine, is rapidly absorbed after oral intake. Peak concentrations in the bloodstream are typically observed within 60 to 90 minutes following administration.

Q: What is the typical duration of effect for Cyclopam Suspension?

A: Regulatory guidelines outline a typical four-times-daily dosing schedule for the medicine. Pharmacokinetic studies describe a mean plasma half-life of 1.8 hours for the Dicyclomine component, which refers to the time it takes for half of the drug to be eliminated from the bloodstream.

Q: Can Cyclopam Suspension affect a person's sleep pattern?

A: Official safety information lists central nervous system (CNS) effects, including drowsiness, sleepiness, and nervousness, as commonly documented adverse reactions associated with the active component. These effects are part of the medicine's safety profile and are described as potentially affecting alertness.

Q: Can taking Cyclopam Suspension lead to constipation?

A: Constipation is listed among the commonly reported side effects associated with the anticholinergic component of this medicine. Information regarding the frequency or severity of this or any other effect can be found in the official safety information.

Q: Is the research evidence for Cyclopam Suspension considered strong or limited?

A: Studies and official information indicate that the evidence base for the components is described as having low to moderate certainty overall. Systematic reviews found that findings were mixed across trials for conditions like Irritable Bowel Syndrome (IBS) and infantile colic.

Q: Does Cyclopam Suspension have any known food interactions?

A: Official regulatory information for the Dicyclomine component indicates that there are no known interactions between the active component and foods or drinks. However, the medicine is typically instructed to be taken after meals and at bedtime.

Q: Are there any common over-the-counter medicines that interact with Cyclopam Suspension?

A: Regulatory documents advise patients to inform their healthcare provider about all co-administered medicines, including over-the-counter (OTC) products, vitamins, minerals, and herbal supplements. This general warning exists due to the potential for certain ingredients to cause additive side effects or affect drug absorption.

Q: Can Cyclopam Suspension interact with vitamin supplements?

A: Official product information advises patients to consult their healthcare provider about the use of all supplements, including vitamins and minerals, due to the potential for interactions with the active components.

Q: Does Cyclopam Suspension interact with herbal remedies?

A: Official warnings advise informing a healthcare provider of any herbal products or supplements being taken. This is due to the possibility that the active drug components may interact with or affect their absorption, potentially leading to increased risk of side effects.

Q: Can Cyclopam Suspension be used for pain relief other than abdominal cramps?

A: Official use descriptions indicate the medicine is intended for targeted relief of abdominal discomfort stemming from intestinal spasms and excess gas accumulation within the gastrointestinal tract. The primary therapeutic focus is on visceral spasmodic pain originating in the gut.

Q: Is there a maximum time length that Cyclopam Suspension is generally used for?

A: Regulatory guidelines establish a 2-week trial period for the Dicyclomine component. Official information notes that if effectiveness is not observed within this specific period, the treatment should be discontinued.

Q: Why is the medicine required to be shaken before use?

A: The suspension is required to be shaken well before use to ensure that the active ingredients are properly and evenly dispersed throughout the liquid preparation. This step is necessary to ensure consistency in the dose received.

Q: What research themes are commonly studied regarding the use of Cyclopam Suspension?

A: Official clinical evidence summaries focus on research themes including the use of the antispasmodic component in Irritable Bowel Syndrome (IBS) in adults. Another area of focus is the use of both the antispasmodic and antiflatulent components in relation to Infantile Colic.

Q: Is Cyclopam Suspension a narcotic or controlled substance?

A: The active component, Dicyclomine, is not classified as a narcotic according to US regulatory agencies. It is also noted in safety summaries as not being habit-forming.

Q: What is the typical concentration of the active ingredient in the suspension?

A: Official regulatory labeling for the oral solution component typically lists a standard concentration of 10 milligrams of Dicyclomine in every 5 milliliters of solution.

Q: What is the common reason for discontinuing the use of Cyclopam Suspension?

A: Reasons for discontinuing the medicine documented in official guidelines include a lack of observed effectiveness after the specified 2-week trial period. Additionally, the occurrence of serious adverse reactions or signs of toxicity is a required reason for cessation.

Q: Are there different strengths of Cyclopam Suspension available?

A: Official regulatory labels for the oral solution component typically list a standard concentration of 10 mg of Dicyclomine per 5 mL. While different strengths may exist in other dosage forms (like tablets), the suspension form usually adheres to this standard.

Q: How does the body generally eliminate the medicine (metabolism and excretion)?

A: The Dicyclomine component is primarily eliminated from the body through the urine (approximately 80 % of the dose). The Simethicone component, being an antiflatulent, is generally not systemically absorbed and is eliminated via the feces.

Q: What is the general classification of the pain it is designed to address?

A: The medicine is designed to address spasmodic pain (cramping) and discomfort related to excess gas within the gastrointestinal tract. This type of pain, originating in the internal organs, is commonly described as visceral pain.

Q: What information should I read before starting Cyclopam Suspension?

A: Regulatory documents advise reviewing key information before starting the medicine. This includes who can or cannot use it (contraindications), a list of potential side effects, and any known drug interactions, as part of the conditions described for use.

Q: Does Cyclopam Suspension contain any sugar or artificial sweeteners?

A: Official labeling for the Dicyclomine oral solution component lists sucrose (sugar) and sorbitol solution among the inactive ingredients used in the preparation. These ingredients contribute to the flavor and vehicle of the liquid medicine.

Q: Can Cyclopam Suspension be used for irritable bowel syndrome (IBS) symptoms?

A: Official indications for the active component Dicyclomine include its use in the treatment of Irritable Bowel Syndrome (IBS). This is generally for managing symptoms like abdominal pain and cramping associated with the condition.

Advertisements

How should Cyclopam Suspension be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal instructions for this oral liquid medicine are derived from the official regulatory labeling for its primary components.


Storage Conditions

Requirement Official Instruction
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F).
Protection Keep in a tight container with a child-resistant closure. Protect from freezing and excessive heat or moisture (e.g., bathroom).
Child Safety Must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired product should be disposed of preferably through a drug take-back program. If this is unavailable, mix the medicine with an undesirable substance (like dirt), place it in a sealed bag, and put it in the household trash. Do not flush the suspension down the toilet or pour it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cyclopam Suspension found in:

A-Z Index: